Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1938997 | 0.95 | ALDH1A1 (0.38) | NAAATSHRHCAR2 | |
| SCHEMBL8860789 | 0.77 | NAAA (0.41) | NAAAEPHX1TSHRPPARGHCAR2 | |
| SCHEMBL7293847 | 0.76 | NAAA (0.40) | NAAAEPHX1TSHRPPARG | |
| SCHEMBL9579423 | 0.76 | NAAA (0.43) | NAAAEPHX1TSHRPPARGHCAR2 | |
| SCHEMBL7296422 | 0.75 | NAAA (0.42) | NAAAEPHX1TSHRPPARGHCAR2 | |
| SCHEMBL7284547 | 0.73 | NAAA (0.38) | NAAAEPHX1TSHRPPARGHCAR2 | |
| SCHEMBL4687165 | 0.73 | NAAA (0.38) | NAAAEPHX1TSHRPPARGGBA2 | |
| SCHEMBL3144750 | 0.73 | NAAA (0.36) | NAAATSHR | |
| SCHEMBL13610202 | 0.73 | GNAI3 (0.47) | NAAAEPHX1TSHRPPARGGBA2 | |
| SCHEMBL11848695 | 0.73 | GNAI3 (0.47) | NAAAEPHX1TSHRPPARGGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795273-B2 | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20080300245-A1 | Pyrazolo[1,5-A]Pyridine-3-Carboxylic Acids as Ephb and Vegfr2 Kinase Inhibitors | IMBACH PATRICIA | 2008-12-04 | — | — | US | disclosed |
| EP-1963316-A2 | PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACIDS AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065664-A2 | PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACIDS AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300245-A1 | Pyrazolo[1,5-A]Pyridine-3-Carboxylic Acids as Ephb and Vegfr2 Kinase Inhibitors | EPHB2, EPHB1, EPHB3 | NAAA 4134/4885EPHX1 137/4885TSHR 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.